Your browser doesn't support javascript.
loading
Prostate cancer reactivates developmental epigenomic programs during metastatic progression.
Pomerantz, Mark M; Qiu, Xintao; Zhu, Yanyun; Takeda, David Y; Pan, Wenting; Baca, Sylvan C; Gusev, Alexander; Korthauer, Keegan D; Severson, Tesa M; Ha, Gavin; Viswanathan, Srinivas R; Seo, Ji-Heui; Nguyen, Holly M; Zhang, Baohui; Pasaniuc, Bogdan; Giambartolomei, Claudia; Alaiwi, Sarah A; Bell, Connor A; O'Connor, Edward P; Chabot, Matthew S; Stillman, David R; Lis, Rosina; Font-Tello, Alba; Li, Lewyn; Cejas, Paloma; Bergman, Andries M; Sanders, Joyce; van der Poel, Henk G; Gayther, Simon A; Lawrenson, Kate; Fonseca, Marcos A S; Reddy, Jessica; Corona, Rosario I; Martovetsky, Gleb; Egan, Brian; Choueiri, Toni; Ellis, Leigh; Garraway, Isla P; Lee, Gwo-Shu Mary; Corey, Eva; Long, Henry W; Zwart, Wilbert; Freedman, Matthew L.
Affiliation
  • Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Zhu Y; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Takeda DY; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Pan W; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gusev A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Korthauer KD; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Severson TM; Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ha G; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Viswanathan SR; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Nguyen HM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Zhang B; Department of Urology, University of Washington, Seattle, WA, USA.
  • Pasaniuc B; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Giambartolomei C; Greater Los Angeles VA Healthcare System, Los Angeles, CA, USA.
  • Alaiwi SA; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Bell CA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • O'Connor EP; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Chabot MS; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Stillman DR; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Font-Tello A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Li L; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Bergman AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Sanders J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • van der Poel HG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gayther SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lawrenson K; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Fonseca MAS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Reddy J; Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Corona RI; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Martovetsky G; Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Egan B; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Choueiri T; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Ellis L; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Garraway IP; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Lee GM; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Corey E; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Long HW; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Zwart W; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Freedman ML; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nat Genet ; 52(8): 790-799, 2020 08.
Article in En | MEDLINE | ID: mdl-32690948
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Nat Genet Journal subject: GENETICA MEDICA Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Nat Genet Journal subject: GENETICA MEDICA Year: 2020 Document type: Article Affiliation country: Country of publication: